Validation of secondary data. Strengths and limitations

被引：49

作者：

Hoffmann, F. ^{[1
]}

Andersohn, F. ^{[1
,2
]}

Giersiepen, K. ^{[1
]}

Scharnetzky, E. ^{[1
]}

Garbe, E. ^{[1
,2
]}

机构：

[1] Univ Bremen, D-2800 Bremen 33, Germany

[2] Charite Univ Med Berlin, Berlin, Germany

来源：

BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ | 2008年 / 51卷 / 10期

关键词：

Secondary data; validation studies; health services research; pharmacoepidemiology; Germany;

D O I：

10.1007/s00103-008-0646-y

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Medical records databases (such as the General Practice Research Database-GPRD) and administrative databases (such as German Statutory Health Insurance (SHI) claims data) are useful sources for pharmacoepidemiology and health services research. However, these data are not primarily collected for research purposes. Validation studies are needed to examine their completeness and accuracy depending on the corresponding research question. This article reviews strategies for checks of internal consistency within the data from one SHI as well as between data from several SHIs and possibilities of internal data validation. Descriptive analyses of consistency can help to determine the integrity of data. The aim of internal validation is to separate uncertain from true cases based on information from secondary data alone or to reproduce known associations within the database. In addition external validation of secondary data is desirable using original prescriptions, medical records, hospital discharge letters and/or patient or physician interviews as a gold standard. A considerable number of external validation studies of diagnostic coding have been conducted within the GPRD. In contrast, such validation studies of German SHI claims data are mostly lacking and are urgently needed in the near future.

引用

页码：1118 / 1126

页数：9

共 41 条

[1]

*AGENS ARB EP METH, 2008, GPS GUT PRAX SEK REV

[2] Use of first- and second-generation cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction [J].